tuberculosis

More than a dozen vaccines for tuberculosis are currently being tested in clinical trials. Some use whole bacteria as BCG does, while others deliver protein subunits or genetic material carried by viral vectors.  

This month marks the 100-year anniversary of BCG, still the only approved vaccine against the lethal pathogen. But there are new vaccines for this wily foe on the horizon.

One hundred years after its invention, BCG has stood the test of time as a vaccine against tuberculosis.

Some researchers have turned their focus to artificial intelligence to study an underused symptom common to most respiratory pathogens—cough.

A recent study elucidates some of the changes that occur in the body after inoculation with a tuberculosis vaccine.

As researchers test existing vaccines for nonspecific protection against COVID-19, immunologists are working to understand how some inoculations protect against pathogens they weren’t designed to fend off.

Studies are underway to test whether giving a shot of BCG vaccine could protect doctors and nurses against COVID-19.

Researchers used a machine-learning platform to test more than 100 million molecules for antibacterial activity.

Tested in patients with the latent form of tuberculosis, the vaccine prevented the development of the active form of infection in 50 percent more individuals compared with unvaccinated patients.

An early-stage, blood-based assay shows potential as a method for sorting patients with suspected TB from those with other respiratory illnesses.

The US Food and Drug Administration green lights a therapy for an extreme form of multidrug resistant TB.

Tweaking the genomes of two phages and combining them with a third phage helped to clear a persistent Mycobacterium infection in the patient.

At least a handful of patients have developed active TB after receiving cancer treatment designed to boost the immune system’s antitumor response.

The information we’ve gathered showed us that warthogs can be used as disease sentinels, avoiding the need to resort to testing valuable or endangered animals.

A new facility located in a congested community with high tuberculosis rates brings basic science and cutting edge techniques into the heart of disease circulation.

The BMJ inquiry finds that researchers presented only select results from animal experiments when applying for funding and approval for human trials.

The new test could improve upon two current methods to diagnose tuberculosis—a skin test or culturing bacteria from saliva, both of which take days.

Research efforts aim to obviate the need for vaccine refrigeration.